Vaccination against SARS-CoV-2 Does Not Protect against the Development of Anosmia in a Hamster Model

Rachel A. Reyna, Jordyn Walker, Brooke Mitchell, Divya P. Shinde, Jessica A. Plante, Scott C. Weaver, Kenneth S. Plante

Research output: Contribution to journalArticlepeer-review

Abstract

Anosmia, a total or partial loss of the ability to smell, is one of the most frequently documented sequelae of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Persistent anosmia is associated with a decrease in quality of life. Here, we assess the impact of virus lineage and vaccination status on anosmia development in the golden Syrian hamster model. To characterize anosmia driven by current variants, we assessed olfactory function in hamsters infected with SARS-CoV-2 lineages A, BA.2, BA.5, BQ.1, and BQ.1.1 using a buried food detection test. We found that significant anosmia occurs upon infection with all variants with a significant correlation between disease severity and degree of anosmia. Moreover, we found that vaccination with either the Pfizer (BNT16b2) or Moderna (mRNA-1273) mRNA vaccines does not protect against anosmia, despite protection against severe disease.

Original languageEnglish (US)
Article number1564
JournalVaccines
Volume11
Issue number10
DOIs
StatePublished - Oct 2023

Keywords

  • SARS-CoV-2
  • anosmia
  • sequelae
  • vaccination

ASJC Scopus subject areas

  • Immunology
  • Pharmacology
  • Drug Discovery
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Vaccination against SARS-CoV-2 Does Not Protect against the Development of Anosmia in a Hamster Model'. Together they form a unique fingerprint.

Cite this